Related Experiment Video
Updated: Apr 28, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Monitoring the distribution of warfarin in blood plasma
Annika M Rosengren1, Björn C G Karlsson1, Ian A Nicholls2
1Bioorganic and Biophysical Chemistry Laboratory, School of Natural Sciences, Linnæus University , SE-391 82 Kalmar, Sweden ; SensiKal AB , Öltappargränd 10, SE-393 64 Kalmar, Sweden.
Abstract:
Warfarin is an anticoagulant drug extensively used in the treatment and prevention of thrombotic disorders. Previous studies have shown that warfarin binds extensively to blood plasma proteins and that only a small fraction of the drug is unbound and thus available for therapeutic function. Both warfarin's narrow therapeutic window and the susceptibility of anticoagulant function to patient-dependent factors necessitate regular monitoring. In this study, we have shown that the lifetimes for each of the various bound and free forms of the drug in blood plasma can be quantified in situ by time-correlated single-photon counting fluorescence spectroscopy over the clinically significant concentration range. A relationship between the blood coagulation and the distribution of fluorescence lifetimes was observed. The in situ detection of clinically relevant concentrations of warfarin in its respective bound and unbound forms could provide a prognostic tool for use in patient treatment.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Therapeutic Drug Monitoring: Drug Analysis Methods
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Drug Concentrations: Measurements
Plasma...

